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Abstract
Background. Validated microsimulation models have been shown to be useful tools in providing support for colorec-
tal cancer (CRC) screening decisions. Aiming to assist European countries in reducing CRC mortality, we developed
and validated three regional models for evaluating CRC screening in Europe. Methods. Microsimulation Screening
Analysis–Colon (MISCAN-Colon) model versions for Italy, Slovenia, and Finland were quantified using data from
different national institutions. These models were validated against the best available evidence for the effectiveness of
screening from their region (when available): the Screening for COlon REctum (SCORE) trial and the Florentine
fecal immunochemical test (FIT) screening study for Italy; the Norwegian Colorectal Cancer Prevention
(NORCCAP) trial and the guaiac fecal occult blood test (gFOBT) Finnish population-based study for Finland.
When published evidence was not available (Slovenia), the model was validated using cancer registry data. Results.
Our three models reproduced age-specific CRC incidence rates and stage distributions in the prescreening period.
Moreover, the Italian and Finnish models replicated CRC mortality reductions (reasonably) well against the best
available evidence. CRC mortality reductions were predicted slightly larger than those observed (except for the
Florentine FIT study), but consistently within the corresponding 95% confidence intervals. Conclusions. Our findings
corroborate the MISCAN-Colon reliability in supporting decision making on CRC screening. Furthermore, our
study provides the model structure for an additional tool (EU-TOPIA CRC evaluation tool: http://miscan.eu-
topia.org) that aims to help policymakers and researchers monitoring or improving CRC screening in Europe.
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Microsimulation models have been shown to be useful
tools in quantifying benefits and harms of colorectal can-
cer (CRC) screening,1–4 but decision makers should be
prudent in determining how much confidence to place in
the results of those models.5,6 Several microsimulation
models are currently used to inform CRC screening pro-
grams,6 but few have been extensively validated.7,8 The
Microsimulation Screening Analysis–Colon (MISCAN-
Colon) model is among this latter group, with extensive
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published information on its model structure, assump-
tions, and validation.9,10
The MISCAN-Colon simulates the sequence that
leads from adenoma to clinical CRC detection, incorpor-
ating parameters based on published data, such as ade-
noma prevalence and lifetime CRC incidence.11–14 Other
crucial parameters, such as duration times from adenoma
formation to CRC, are impossible to observe—in an ethi-
cally acceptable manner—and could not be directly based
on existing evidence. Those parameters were, however,
inferred using results from randomized control trials
(RTCs) investigating the effectiveness of CRC screen-
ing.8,15–17
Although the MISCAN-Colon model structure has
been validated,16 it is still unclear how reliable the
MISCAN-Colon results may be considering different
populations. CRC incidence rates varied remarkably
across countries,14 and this may be caused by variations
in the underlying cancer risk (due to genetics, lifestyle,
and socioeconomic factors possibly affecting natural his-
tory of the disease). Thus, the EU-TOPIA project (EU-
Framework Programme, Horizon 2020–634753) decided
to investigate the robustness of the MISCAN-Colon
structure across a variety of countries, aiming to further
generalize and use the MISCAN-Colon model across
Europe. The final objective of EU-TOPIA is to develop
a standardized online version of the model (EU-TOPIA
CRC evaluation tool; http://miscan.eu-topia.org) that
allows European policymakers to quantify and predict
CRC screening benefits in their country.
In this study, we developed and validated three
European regional model versions, providing modelling
results that support the reliability of MISCAN-Colon




MISCAN-Colon is a stochastic microsimulation model
that simulates the life histories of many individuals from
birth to death. In each simulated individual, zero, one,
or more than one adenoma may occur. These adenomas
might progress in size and might become malignant.
Survival after CRC diagnosis is modelled depending on
age, stage, and localization of cancer at diagnosis.
Screening may alter the simulated life histories, detecting
some CRCs at an earlier stage or preventing them by
removing a precancerous lesion. Comparing life histories
with and without screening, MISCAN-Colon quantifies
the effectiveness of CRC screening. In Europe, it has
been used to design, monitor, and evaluate the Dutch
CRC screening program, predicting its future benefits.4
The Dutch MISCAN-Colon model version was calibrated
to age- and stage-specific (UICC TNM stage classification)
CRC incidence rates observed in the Netherlands in 1999-
2003 (see Supplementary Methods for more information
on the MISCAN-Colon structure, underlying assump-
tions, and results of the Dutch model version).18
Survival rates were based on data from the South of the
Netherlands.19 Specific model parameters, such as ade-
noma dwell time and the preclinical duration of CRC,
were calibrated replicating outcomes of CRC screening
RCTs8 and, subsequently, validated to the results of the
NORCCAP trial.16
Development of Country-Specific MISCAN-
Colon Model Versions for Italy, Slovenia, and
Finland
In this study, we developed three new country-specific
model versions (Italy, Slovenia, and Finland) that along
with the Dutch model version are aiming to be represen-
tative of all regions in Europe (Italy for the Southern;
the Netherlands for Western; Slovenia for Eastern;
and Finland for Northern European countries). Italy,
Slovenia, and Finland were countries with research
institutions directly involved in the EU-TOPIA project.
In developing each model, we used a specific calibration
process (Supplementary Methods). Briefly, we started
using the previously calibrated Dutch model version,
adjusting demographic and CRC epidemiological
assumptions such as population size, all-cause mortality,
CRC relative survival by stage, and cancer localization
(using the country-specific data in the period before the
introduction of screening). Then, we initially calibrated
the model parameters behind age-specific adenoma onset
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and distribution of CRC stages (parameters that lead to
country-specific CRC incidence and stage distribution),
assuming the same parameters of the Dutch model for
the adenoma progression and the preclinical duration of
CRC. Calibration was performed using country-specific
CRC incidence rates and CRC stage distribution
(reported in the prescreening period). We first validated
the model versions replicating the data that were used in
the calibration process (internal validation). Then, the
models were externally validated (i.e., model replication
of data not used in calibrating the models) against the
best evidence for screening effectiveness for the respec-
tive countries (when the evidence was available, i.e., for
Italy and Finland). A decision algorithm was used to
select the evidence to perform an external model valida-
tion: four published studies were selected from a sys-
tematic review assessing the effectiveness of screening on
CRC mortality in Europe (see Supplementary Methods
for more details on the selection of the studies). In order
to perform an external validation, the models were
accordingly adjusted to replicate the study-specific popu-
lation and screening pattern. When evidence for screen-
ing effectiveness was not available in the specific country
or its European region (i.e., Slovenia), model versions
were only internally validated. If models failed internal
or external validation, we reiterated the developing pro-
cess relaxing the assumption on adenoma and CRC pro-
gression parameters (by re-calibrating these parameters
as well).
Data used for calibration, internal validation, and
external validation are reported below for each model
version and, extensively, in Table 1 and Table 2. Primary
validation targets were CRC incidence and mortality
rates and stage distribution observed in the prescreening
period for internal validation; and CRC mortality reduc-
tions due to screening for the external validation (CRC
incidence reductions were also investigated and reported
in Supplementary Methods). In the (internal or external)
validation procedures, a model replication was consid-
ered ‘‘consistent’’ when the simulated model prediction
was estimated within the 95% confidence intervals (95%
CI) of the corresponding observed outcome. When 95%
CIs were not reported in the study or in the data source,
those were computed assuming Poisson or binomial
distributions.
Data Sources for Calibration and External
Validation
The Italian Model Version. We used the IARC cancer
incidence in five continents databases (Vol. IX, period
1998–2002) to inform and calibrate the Italian model.14
Cancer registry data from Turin, Milan, Genoa,
Florence, and Prato were excluded due to the early intro-
duction of population-based screening programs or pilot
studies in those areas (Supplementary Methods).20–22
Stage distribution parameters were calibrated using data
from the Cancer Screening National Monitoring
reports.23 We modelled the age distribution of the Italian
population in 1998 using data from the Human
Mortality Databases.24 CRC relative survival was
adjusted as described in Supplementary Methods, using
data published by EUROCARE group.25 Two studies
were selected aiming to (externally) validate the Italian
model: the ‘‘once-only’’ sigmoidoscopy screening or
Screening for COlon REctum (SCORE) trial; and the
cohort study assessing FIT screening in Florence.21,26
The first was a multicenter RCT conducted in Italy
assessing the efficacy of FS screening (offered once in life
at 55–64 years of age).21 Individuals were randomly
assigned to intervention group (FS, n = 17,148) or con-
trol group (no further contact, n = 17,144), between
1995 and 1999. Incidence and mortality follow-up ended,
respectively, December 31, 2007, and December 31,
2008. The second study was a population-based cohort
study performed in Florence to test biennial FIT screen-
ing effectiveness.26 Subjects undergoing FIT screening
between 1993 and 1999 (attenders; n = 6,961) were com-
pared to unscreened individuals from the same district
(invited but not attenders; n = 26,285). Follow-up ended
on December 31, 2008.
The Slovenian Model Version. We calibrated the
Slovenian model using CRC incidence and stage distribu-
tion data from the cancer registry of Slovenia (2004–
2008, the period before implementation of organized FIT
screening).13 The model was adjusted to simulate the
Slovenian population in 2008 (based on data from the
Human Mortality Databases).24 CRC relative survival
was adjusted as described in Supplementary Methods,
using data published by EUROCARE group.27 As no
published evidence was retrieved for CRC screening
effectiveness in Eastern Europe, we could not externally
validate the Slovenian model.
The Finnish Model Version. We calibrated the Finnish
MISCAN-Colon version using CRC incidence and stage
distribution data observed in the Finnish Cancer
Registry between 1999 and 2003,12 before the introduc-
tion of a population-based screening pilot study investi-
gating the efficacy of gFOBT screening in 2004.28 CRC











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































stage distribution data needed to be converted before
performing the model calibration due to the different
CRC staging classification in Finland (different from the
UICC TNM stage classification). The conversion was
performed as follows: localized CRCs were assumed for
1/3 as TNM stage I and for 2/3 as TNM stage II (based on
the CRC stage proportions observed in the Netherlands,
Italy, and Slovenia); regional (CRCs nonlocalized, only
regional lymph node metastases or with no information on
extent) as TNM stage III; and distant (CRCs metastasized
further than regional lymph nodes) as TNM stage IV. We
used the model to simulate the 1999 age-specific Finnish
population based on data from the Human Mortality
Databases.24 CRC relative survival was adjusted as
described in Supplementary Methods, using data published
by EUROCARE group.27 Two studies were selected to
(externally) validate the Finnish model: the Norwegian
Colorectal Cancer Prevention (NORCCAP) Trial and the
Finnish gFOBT screening RCT.28,29 The first was an RCT
conducted in Norway assessing the effectiveness of FS on
CRC incidence and mortality (with 100,210 individuals
aged 50–64 years randomized to screening or control
group). Screening was performed between 1999 and 2001
and follow-up ended December 31, 2011 (10.9 years of fol-
low-up).29 The second study was a large randomized study
gradually performed from 2004 to 2012 in Finland.
Individuals aged 60 to 69 years were randomly allocated to
screening (biennial gFOBT screening; n = 180,210) and to
a control group (n = 180,282).28 The median follow-up
was 4.5 years (maximum of 8.3 years).
Results
Internal Validation
In the absence of screening, the model versions predicted
CRC incidence and CRC stage distribution consistently in
Italy, Finland, and Slovenia in the period before the intro-
duction of screening (Figure 1). However, CRC incidence
rates were slightly overestimated in Italy (1998–2002)
among individuals aged 85 years or older, and in Slovenia
(2004–2008) among those aged 75 to 79 or older than 85
years. CRC mortality rates (data not used for calibrating
the models) were underestimated to some extent among
elderly individuals in Italy (1998–2002; age groups: 75–79;
and 85 years), in Slovenia (2004–2008; those aged 85
years or older), and in Finland (1999–2003; 85 years).
External Validation
When an external validation was performed (Italy and
Finland), the model versions consistently replicated
CRC mortality reductions due to FS, FIT, or gFOBT
screening. The Italian model version predicted a 30%
lower CRC mortality after 11 years of follow-up in the
intervention arm of the SCORE trial (FS), consistently
with the trial outcomes (simulated relative risk [RR] =
0.70; observed RR = 0.78, 95% CI: 0.56–1.08; Table 3).
Moreover, CRC mortality reduction was also consis-
tently predicted in the Florentine FIT screening ‘‘atten-
ders’’ group (36% lower compared to not attenders,
RR = 0.64) after 11 years of follow-up (observed RR =
0.59, 95% CI: 0.37–0.93; Table 3). Nevertheless, CRC
deaths were overestimated in replicating both screening
and control arm of the SCORE trial, with CRC cumula-
tive mortality overestimated after 9 follow-up years of the
SCORE control arm and underestimated in the first 4
follow-up years of the SCORE screening arm (Figure 2).
CRC cumulative incidence rates were also underestimated
replicating the controls of the FIT Florentine study (after
8 years of follow-up; Supplementary Methods).
Considering the Finnish model version, CRC mortal-
ity reductions due to screening were simulated in line,
respectively, with the results of the NORCCAP trial
(simulated RR = 0.71 and observed RR = 0.73, 95%
CI: 0.56–0.94) and the Finnish population-based study
(simulated RR = 0.92 and observed RR = 1.04, 95%
CI: 0.84–1.28; Table 3). CRC cumulative mortality was
underestimated by the Finnish model replicating the
screening arm of NORCCAP trial (at 4 years of follow-
up; Figure 2), whereas CRC cumulative incidence was
underestimated and overestimated, respectively, in the
controls of the gFOBT population-based study (between
4 and 6 years of follow-up) and in the screening arm of
the NORCCAP trial (after 10 years; Supplementary
Methods).
All three models were developed assuming the same
parameters of the Dutch model version for the adenoma
progression and the preclinical duration of CRC (the
recalibration of those model structural parameters was
not performed).
Discussion
In this study, we developed three European regional
MISCAN-Colon model versions varying only a mini-
mum set of model parameters (adenoma onset and CRC
stage distribution at diagnosis). Those versions of the
model accurately estimated country-specific CRC stage
distribution, incidence, mortality rates (in the prescreen-
ing period; all model versions), and cancer-specific
mortality reduction due to screening (only Italian and
Finnish model versions). Using the same adenoma
8 MDM Policy & Practice 00(0)
progression times and preclinical duration of CRC across
quite diverse countries and screening settings, our find-
ings may suggest that the natural history of CRC does
not vary remarkably across the European countries.
Model validation is an important process in the model
development, providing measurable insights on the
capacity of the models to correctly estimate and predict
the disease-specific outcomes and the potential benefits
of screening. Five levels of model validity have been pro-
posed by Eddy et al.: face, internal, cross, external, and
predictive validity.30 In this study, we assessed the valid-
ity of our model versions using two of those levels: the
internal (for Italy, Finland, and Slovenia) and the exter-
nal validity (for Italy and Finland). We found consistent
results when we validated our model versions. However,
some specific outcomes were not predicted within the
95% confidence interval of the corresponding observed
outcome. CRC incidence rates without screening were
overestimated by the Italian and Slovenian model version
among individuals aged 85 years or older. A likely
Figure 1 Simulated and observed colorectal cancer incidence, mortality rates (A), and stage distributions (B) in the period before
the introduction of screening in Italy (1998–2002), Slovenia (2004–2008), and Finland (1999–2003). CRC, colorectal cancer.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































explanation for this discrepancy is the potential underre-
porting of CRC at older ages due to frailty and comor-
bidities of this elderly population.31 The model also
overestimated CRC incidence in the control group of the
Finnish gFOBT screening study (Supplementary
Methods). One explanation may be the potential contam-
ination of screening in the control group, especially in the
early years of the RCT. This hypothesis is supported by
the study of Maklin et al. showing that the colonoscopy
use in the control group was nearly two thirds of that in
the screening group between 2004 and 2010 and nearly
83% in the first 2 years.32 Thus, it may reasonable to
expect that in the control group some CRCs may be diag-
nosed earlier with better survival as a result.
In our external validations, CRC cumulative incidence
rates were simulated inconsistent with those observed in
the last follow-up years of two studies (FIT Florentine
study and NORCCAP trial). As data on CRC risk
among nonparticipants in screening was limited, those
discrepancies may be a direct consequence of the assump-
tions made to incorporate that lacking information in
our model versions. Finally, we also found that the num-
ber of CRC deaths predicted by the Italian model version
was higher than the actual number observed in the
Figure 2 Simulated and observed cumulative colorectal cancer mortality in SCORE trial, Florentine FIT population-based
screening program, NORCCAP trial, and Finnish gFOBT population-based study. CRC, colorectal cancer.
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SCORE trial, while CRC mortality outcomes were con-
sistently predicted for the FIT Florence study. It might
seem conflicting, but it may be explained considering
the input data used in the model. As MISCAN-Colon
does not incorporate changes in CRC relative survival
over time (only age-, stage-, and localization-specific
differences),9 we informed our model using CRC rela-
tive survival data observed in the years close to the
study’s randomization period. However, in Italy, the 5-
year CRC relative survival sharply increased (from
53.9% to 59%/61% [colon/rectum cancer]) during 1994
to 2007,25,27 resulting in an overestimation in replicat-
ing CRC deaths of the SCORE trial. In contrast, in
Florence, the 5-year CRC relative survival was more
stable with small improvement during 1995 to 2004,33
allowing, therefore, accurate CRC mortality model
replications.
Model consistency was evaluated considering the 95%
confidence intervals. This decision could be disputed,
arguing that models and corresponding predictions could
have benefited using more narrow confidence intervals
(i.e., 50% CI) in the validation process. However, one
should be careful with such considerations. CI represents
the level of the plausibility of an estimation: from an
inference point of view, a 50% CI reflects an interval for
which we are 50% confident that the real study value
falls within its limits. Using a narrower CI threshold in
our model validation may lead us to select more specific
models (good fit with the select study) but with lower
confidence in their inference (50% confident to be close
to the real ‘‘population’’ value). Hence, we decided to use
the established 95% CIs and jointly validate our models
against several validation targets (simultaneously), pro-
viding more robustness and confidence in our model
structure.
Validation assessments, as performed in our study, are
important in making a microsimulation model clinically
useful.6 MISCAN-Colon model is now validated against
6 of 9 RCTs included in the Cochrane Library on the
benefits of CRC screening: 3 of 4 gFOBT trials,34–36 and,
including the findings of this study, 3 of 5 FS trials.15,21,29
Model validation in the remaining 2 FS trials may not be
performed due to, respectively, the frequent occurrence
of opportunistic screening and the small number of parti-
cipants.37,38 Moreover, MISCAN-Colon model is now
also validated using population-based results on the
effectiveness of FIT and gFOBT screening, with success-
fully fitting outcomes.26,28
Still, some limitations are noteworthy. First, when
validating our models, we did not assume different
screening tests sensitivity according to the location of
adenomas. Some studies indicated that sensitivity of stool
tests might vary between right-sided and left-sided pre-
malignant lesions, but there is not a full medical consen-
sus on this hypothesis.37,39,40 Second, our models were
not stratified by gender. Third, MISCAN-Colon does
not currently simulate adenoma histology (villous histol-
ogy or advanced atypia). Thus, after a follow-up colono-
scopy investigation, we categorized low- and high-risk
adenoma individuals for post-colonoscopy surveillance
using the number and size of the found adenomas.
Fourth, we informed our models with data collected in
absence of screening. Although that data could be
considered outdated, it guaranteed a reliable model cali-
bration without needing detailed information on the
screening program (i.e., implementation, invitation,
adherence, management, protocols, and regional hetero-
geneity). Finally, the Slovenian MISCAN-Colon model
version was only internally validated, limiting therefore
the extrapolation of our modelling results to the Eastern
European region. However, in our study we showed that
MISCAN-Colon was internally validated in all European
regions. In addition, the Slovenian model version was
calibrated using the same process of the other model ver-
sions included and validated in this study. Hence, given
the currently available evidence, we think that MISCAN-
Colon can also be a useful tool for evaluating CRC
screening also in the Eastern European region.
Notwithstanding these limitations, our results have
important clinical implications. We derived our models
with the same assumptions on adenoma progression and
preclinical duration of CRC (important parameters
for simulating the adenoma-carcinoma sequence) as
calibrated and validated for the Dutch version of the
MISCAN-Colon model. Rutter et al. have shown that
this assumption may have a substantial impact on
the external validity of the MISCAN-Colon model.
However, our study suggested that those parameters can
be reliable across different model versions. This might
indicate that the natural history of CRC may not vary
substantially across Europe: when differences in CRC
incidence rates are present between countries,14 those
may be assumed as related to country-specific differences
in onset of adenomas (i.e., different prevalence of well-
known CRC-associated lifestyle factors) rather adenoma-
carcinoma progression. The findings of our study might
support some considerations in scientific literature. Since
1988, increasing trends in CRC incidence were observed
in 26 European countries due to societal changes in life-
style factors, such as diet, obesity, and low physical activ-
ity.41 Biologically, it might be possible that CRC-
associated risk factors are influencing merely the onset of
12 MDM Policy & Practice 00(0)
adenomas, whereas the effects of the risk factors on the
adenoma progression rates are unlikely. This might be
seen investigating the associations between lifestyle fac-
tors and, respectively, incidence of CRCs and occurrence
of adenomas. Only small differences in the relative risks
(effect size of the associations) were observed between
association to CRC and to adenoma.42–45 Our modelling
results have also important future implications for
MISCAN-Colon because further standardizations, such
as an online model version, are therefore possible. For
instance, country-specific differences may be included in
the MISCAN-Colon model merely adjusting the ade-
noma onset parameters (with multiplicative factors, as
done in the external validations included in this study).
EU-TOPIA is currently using the findings of this study to
structure an online tool that allows users to upload and
use their country-specific data (demographic, epidemiolo-
gical, and CRC screening information) for simulating
and monitoring future benefits of CRC screening (the
EU-TOPIA evaluation tool; http://miscan.eu-topia.org).
European stakeholders will be able to quantify short- and
long-term impacts of CRC screening in their countries.
Furthermore, the EU-TOPIA evaluation tool allows
users to provide the last available epidemiological and
screening data (i.e., CRC survival, invitation coverage, or
target population) for providing reliable future predic-
tions (period 2020–2050). From a policy perspective, this
tool can help quantify the effects of current limitations in
the CRC screening program, evaluate the impact of
removing those limitations, and define appropriate bud-
gets and roadmaps for reducing the burden of CRC.
However, our modelling findings (and the EU-TOPIA
evaluation tool) are specific to Europe. Although
MISCAN-Colon seems to be reliable across different
populations and screening settings, further assessments
are needed before extrapolating the modelling results of
our model structure to populations of other continents
such as Asia, America, and Africa. Nevertheless, the
methodology developed in this study (the calibration and
validation process) could be extended to other parts of
the world. We have successfully developed MISCAN-
Colon model versions for the United States, Canada, and
Australia (a model version for China is currently under
development). Taking these models as a base, similar
online evaluation tools could be developed, for example,
for different states in the United States, or countries in
Asia.
In conclusion, our findings corroborate the MISCAN-
Colon reliability in supporting decision making on CRC
screening, especially among European countries. Further-
more, our study provides the regional model versions and
the modelling results that can be used to structure an addi-
tional online tool able to quantify, monitor, or improve
CRC screening in Europe.
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